Sinotau Pharmaceutical Group

3 in Phase 3

Quick facts

Phase 3 pipeline

Lutetium[177Lu] Oxodotreotide Injection · Oncology
Lutetium-177 oxodotreotide is a radiolabeled somatostatin analog that binds to somatostatin receptors on neuroendocrine tumor cells and delivers targeted radiation therapy.
XTR004 · Diabetes
XTR004 is a small molecule targeting the SGLT2 receptor.
XTR006 · Diabetes
XTR006 is a small molecule that targets the SGLT2 receptor.

Phase 2 pipeline

XTR003

Phase 1 pipeline

89Zr-CD147 · Oncology
Targeting CD147
Drug: [18F]florbetaben

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors: